CRISPR Therapeutics (CRSP) director receives 13,000 stock options at $51.84 strike

Rhea-AI Filing Summary

CRISPR Therapeutics AG director George Simeon received a grant of stock options for 13,000 common shares. The options carry an exercise price of $51.84 per share and expire on June 5, 2036. This is a compensation-related award, not an open-market trade.

According to the vesting terms, the options vest in 12 equal monthly installments, subject to his continued service. The first installment vests on June 30, 2026, and the final installment vests on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider George Simeon

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 13,000 options Exercise price: $51.84 per share Expiration date: June 5, 2036 +4 more

7 metrics

Option grant size 13,000 options Stock Option (Right to Buy) granted to director

Exercise price $51.84 per share Strike price for stock options

Expiration date June 5, 2036 Option expiration

Shares underlying options 13,000 common shares Underlying security for the option grant

Holdings after grant 13,000 derivative securities Total stock options following transaction

Vesting start date June 30, 2026 First monthly vesting installment

Vesting schedule length 12 monthly installments Subject to continued service

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, vesting, Annual Meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"the options will vest and become exercisable in 12 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting financial

"the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

George Simeon

(Last) (First) (Middle)

929 MAIN STREET

SUITE 200

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$51.84	06/05/2026		A		13,000		(1)	06/05/2036	Common Shares	13,000	$0	13,000	D

Explanation of Responses:

1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

	/s/ Sasha Keough, attorney-in-fact for Simeon George	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CRISPR Therapeutics (CRSP) director George Simeon report in this Form 4?

George Simeon reported a grant of stock options covering 13,000 CRISPR Therapeutics common shares. These options are a compensation-related award, not an open-market purchase or sale, and were received at a per-share exercise price of $51.84.

What are the key terms of George Simeon’s CRSP stock option grant?

The grant consists of options to buy 13,000 common shares at an exercise price of $51.84 per share. The options expire on June 5, 2036, giving a long exercise window tied to Simeon’s continued service to the company.

How do the CRSP stock options granted to George Simeon vest?

The options vest in 12 equal monthly installments, subject to continued service. Vesting begins on June 30, 2026, with the final installment vesting on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting.

Is George Simeon’s CRSP Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant of stock options classified as a “Grant, award, or other acquisition.” It is not an open-market buy or sell; instead, it represents compensation that may be exercised later at $51.84 per share if conditions are met.

How many CRSP derivative securities does George Simeon hold after this option grant?

Following this transaction, Simeon holds 13,000 stock options related to CRISPR Therapeutics common shares. These options represent rights to buy shares at $51.84 each, subject to the disclosed vesting schedule and the expiration date of June 5, 2036.